常见风湿病未发表临床试验的情况
该研究利用ClinicalTrials.gov识别五种风湿病(SLE、血管炎、脊柱关节炎、SS和PsA)完成超过30个月的注册随机对照试验,发现203项研究中17.2%未发表,涉及4281名受试者数据。阳性主要结局与发表独立相关(HR 1.55;95%CI:1.09,2.22),作者呼吁推动所有风湿病随机对照试验发表并重新分析未发表试验。
要点
- 五种风湿病完成超过30个月的注册随机对照试验中17.2%未发表,涉及4281名受试者数据。
- 已发表试验中3期随机对照试验比例更高(57.1% vs 未发表28.6%,P<0.05)。
- 阳性主要结局与发表独立相关(HR 1.55;95%CI:1.09,2.22)。
核心结论
- 近五分之一的风湿病随机对照试验在试验完成后2年仍未发表,发表与阳性主要结局指标相关。
- 作者认为应努力鼓励所有风湿病随机对照试验发表,并重新分析先前未发表的试验。
研究设计与样本
- 利用ClinicalTrials.gov识别五种风湿病(SLE、血管炎、脊柱关节炎、SS和PsA)完成超过30个月的注册随机对照试验,共203项符合纳入标准。
- 通过NCT ID号和结构化文本检索 publication 数据库识别索引出版物,从摘要和新闻稿中识别未发表研究结果,并通过调查通讯作者评估未发表原因。
主要发现
- 203项符合纳入标准的研究中17.2%未发表,代表4281名试验参与者的数据。
- 已发表试验中3期随机对照试验比例高于未发表试验(57.1% vs 28.6%,P<0.05)。
- 已发表试验中阳性主要结局指标比例高于未发表试验(64.9% vs 25.7%,P<0.001)。
- 多变量Cox比例风险模型中,阳性结局与发表独立相关(风险比1.55;95%CI:1.09,2.22)。
- 10项未发表试验的通讯作者提及未发表原因包括:正在准备稿件(50.0%)、申办方/资助方问题(40.0%)和结果不重要/阴性(20.0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Randomized controlled trials (RCTs) provide high-quality evidence for treatment efficacy, but many RCTs remain unpublished. The objective of this study was to describe the proportion of unpublished RCTs in five rheumatic diseases and to identify factors associated with publication. METHODS: Registered RCTs for five rheumatic diseases (SLE, vasculitis, spondyloarthritis, SS and PsA) with over 30 months since study completion were identified using ClinicalTrials.gov. Index publications were identified by NCT ID numbers and structured text searches of publication databases. The results of unpublished studies were identified in abstracts and press releases; reasons for non-publication were assessed by surveying corresponding authors. RESULTS: Out of 203 studies that met eligibility criteria, 17.2% remained unpublished, representing data from 4281 trial participants. Higher proportions of published trials were phase 3 RCTs (57.1% vs 28.6% unpublished, P < 0.05) or had a positive primary outcome measure (64.9% vs 25.7% unpublished, P < 0.001). In a multivariable Cox proportional hazards model, a positive outcome was independently associated with publication (hazard ratio 1.55; 95% CI: 1.09, 2.22). Corresponding authors of 10 unpublished trials cited ongoing preparation of the manuscript (50.0%), sponsor/funder issues (40.0%) and unimportant/negative result (20.0%) as reasons for lack of publication. CONCLUSIONS: Nearly one in five RCTs in rheumatology remain unpublished 2 years after trial completion, and publication is associated with positive primary outcome measures. Efforts to encourage universal publication of rheumatology RCTs and reanalysis of previously unpublished trials should be undertaken.
引用
- Pedersen C, Tai S, Valley E, et al. Unpublished clinical trials of common rheumatic diseases. Rheumatology (Oxford). 2023. PMID: 36971599. doi:10.1093/rheumatology/kead141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。